Hepatitis C Fact Sheet
                    What is Hepatitis C?
                    Hepatitis C is a blood-borne, infectious disease of the liver`, which can lead to serious liver
                        problems, including cirrhosis (scarring of the liver) and liver cancer. Hepatitis C virus (HCV)
                        is the leading cause of liver transplants in the United States.1
                    Approximately 75 to 85 percent of people exposed to the hepatitis C virus (HCV) develop chronic
                        infection, a long-term illness that occurs when HCV remains in a person's body. Of those,
                        approximately 60 to 70 percent of people will develop chronic liver disease, and up to 20
                        percent will develop cirrhosis, if HCV remains untreated.1 Chronic
                        liver disease due to HCV is marked by inflammation of the liver tissue with gradual damage or
                        scarring of liver tissue (fibrosis). Over many years, some patients may develop cirrhosis where
                        the scarring involves most of the liver. Patients with cirrhosis are at increased risk for
                        developing liver cancer.2
                    There are at least six major known strains, or genotypes, of HCV and over 50 subtypes. Genotype
                        refers to the genetic make-up of an organism or a virus. Genotype 1 is the most common form of
                        HCV in the United States and accounts for about 75 percent of cases. Patients with genotypes 2
                        and 3 represent only 10 to 20 percent of the HCV population in the United States.3
                    How Common is Hepatitis C?
                    An estimated 4 million people in the United States have HCV infection. Often dubbed the "silent
                        disease," HCV infects approximately 17,000 people each year, and many are asymptomatic for years
                        after initial infection. Every year, the disease causes an estimated 8,000 to 10,000 deaths in
                        the United States.1,4 Chronic viral hepatitis
                        infections are three to five times more frequent than HIV infection in the United States.4
                    The rate of HCV infection is higher among African Americans.4 The
                        HCV-related mortality rate among Latinos is nearly twice the rate among non-Latino whites. HCV
                        in Latinos causes more aggressive inflammatory activity and fibrosis, greater disease
                        progression and greater risk of cirrhosis than in non-Latino whites or African-Americans.5
                    How is HCV Spread?
                    HCV is spread primarily through contact with infected blood. Common routes of infection
                        include:3,6,7
                    
                        - Receiving blood, blood products and organs before June 1992
 
                        - The use of shared or unsterilized needles and injection equipment (e.g. injection drug
                            use)
                        
 
                        - Birth to an HCV-infected mother
 
                        - Hemodialysis for kidney failure
 
                        - Accidental exposure to a needle contaminated with infected blood
 
                        - Sexual contact with an HCV-infected person
 
                        - Intranasal cocaine use through shared paraphernalia
 
                        - Use of unsterilized and infected needles or ink for tattooing and piercing
 
                        - Sharing infected personal items (e.g., razors, toothbrushes) and other household items that
                            may have blood on them
                        
 
                    
                    What are the Symptoms?
                    Patients with chronic HCV infection generally experience no signs or symptoms during early stages
                        of infection. When symptoms do occur, they are generally mild, nonspecific and intermittent.
                    Symptoms may include:3,8
                    
                        - Fatigue
 
                        - Fever
 
                        - Nausea or poor appetite
 
                        - Muscle and joint pains
 
                        - Tenderness in the area of the liver
 
                        - Jaundice
 
                        - Dark urine
 
                        - Clay-colored stool
 
                    
                    When do Symptoms Develop?
                    Many patients experience no symptoms and, for those who do, symptoms may not show up for years or
                        even decades. Chronic liver disease in HCV-infected people usually progresses slowly without
                        detection. Many times, HCV infection is not recognized until it is identified when people are
                        screened for blood donations or through routine examinations.6 HCV
                        is not routinely screened for in regular examination, so it's important that someone who may
                        have been exposed talk to a doctor. When left undiagnosed, HCV can lead to serious liver
                        problems, including cirrhosis and liver cancer, and is the most common reason for liver
                        transplantation in the United States.1
                    What Should People do if They Think They Have Been Exposed to HCV?
                    People concerned about being exposed to HCV should consult their health care professional about
                        screening for HCV infection. Common tests include:1,9,10
                    
                        - Antibody detection tests: The antibody detection test determines the
                            presence of antibodies of the virus, indicating exposure to HCV. An antibody is a substance
                            found in the blood that the body produces in response to a virus. A doctor will likely order
                            a second test to confirm whether the virus is still present in the bloodstream.
                        
 
                        - Virus detection tests: The virus detection test identifies whether the
                            virus is still present, indicating an active infection of HCV. This test may also be used
                            after treatment to determine if the virus has been eliminated from the body.
                        
 
                        - Liver biopsy: A liver biopsy is a procedure to remove a small piece of the
                            liver so it can be examined with a microscope for signs of damage or disease. A liver biopsy
                            is not necessary for diagnosis but is used to determine the severity of the disease and
                            permanent damage. It is also helpful in determining the cause of the damage.
                        
 
                    
                    Can HCV be Treated?
                    Currently, there is no vaccine against HCV. Sustained virological response (SVR) may be achieved
                        using the current treatment options. This means that HCV is no longer detected in the blood six
                        months after treatment is completed.6
                    What are the Treatment Options for HCV?
                    Currently, the standard of care for the treatment of HCV is pegylated interferon in combination
                        with ribavirin. This combination therapy is typically a 24-week (for genotypes 2 and 3) or
                        48-week (for genotypes 1 and 4) course. Research has shown that combination therapy with
                        pegylated interferon and ribavirin can result in undetectable levels of HCV in 40-50 percent of
                        people with genotype 1 and 70-80 percent of people with genotypes 2 and 3.11,12,13,14
                    Are There New Treaments Currently under Investigation for HCV?
                    There are two new types of compounds currently under development by several pharmaceutical and
                        biotechnology companies in the United States.
                    
                        - Protease inhibitors: Protease inhibitors are compounds that interfere with
                            the ability of certain enzymes to break down proteins. Protease inhibitors can keep a virus
                            from making copies of itself within an infected cell.
                        
 
                        - Polymerase inhibitors: Polymerase inhibitors are molecules that bind to
                            polymerase enzymes, which are responsible for the formation of new RNA from an existing
                            strand of RNA. By binding to the HCV RNA-dependent polymerase enzymes, these inhibitors
                            prevent the formation of new RNA.15
 
                    
                    Where Can One Find More Information About HCV?
                    For more information about HCV, please visit www.HepCFight.com
                        where people with HCV, their family and friends will find various online resources.
                 
                
                    
                    
                        
                            1 Centers for Disease Control. "Hepatitis C FAQs for the
                            Public," available online at http://www.cdc.gov/hepatitis/C/cFAQ.htm.
                            Last accessed March 7, 2010.
                        
                        
                            2 University of Maryland Medical Center. "Liver Disease,"
                            available online at http://www.umm.edu/liver/chronic.htm.
                            Last accessed April 1, 2010.
                        
                        
                            3 National Digestive Diseases Information Clearinghouse.
                            "Chronic Hepatitis C: Current Disease Management," available online at http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/.
                            Last accessed February 16, 2010.
                        
                        
                            4 Colvin, HM, Mitchell, AE. Hepatitis and Liver Cancer: A
                            National Strategy for Prevention and Control of Hepatitis B and C. http://www.nap.edu/openbook.php?record_id=12793&page=1.
                            Accessed March 7, 2010.
                        
                        
                            5 Rodriguez-Torres M. "Peginterferon Alfa-2a and
                            Ribavirin in Latino and Non-Latino Whites with Hepatitis C." The New England
                                Journal of Medicine. 2009;360:257-267.
                        
                        
                            6 Center for Disease Control and Prevention. "Hepatitis C
                            Information for Health Professionals," available online at http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm.
                            Last accessed on February 16, 2010.
                        
                        
                            7 New York Department of Health and Mental Hygiene.
                            "Hepatitis C." http://home2.nyc.gov/html/doh/html/cd/cdhepc-fs4a.shtml.
                            Last accessed on April 2, 2010.
                        
                        
                            8 Mayo Clinic. "Hepatitis C Symptoms," available online
                            at http://www.mayoclinic.com/health/hepatitis-c/DS00097/DSECTION=symptoms.
                            Last accessed on March 7, 2010.
                        
                        
                            9 Lab Tests Online. "Hepatitis C. The Test," available
                            online at http://www.labtestsonline.org/understanding/analytes/hepatitis_c/test.html.
                            Last accessed March 8, 2010.
                        
                        
                            10 National Digestive Diseases Information
                            Clearinghouse. "Liver Biopsy," available at http://digestive.niddk.nih.gov/ddiseases/pubs/liverbiopsy/.
                            Last accessed on March 8, 2010.
                        
                        
                            11 Fried MW, et al. Peginterferon Alfa-2a Plus Ribavirin
                            for Chronic Hepatitis C Virus Infection. N Engl J Med 2002; 347
                            (13):975-982.
                        
                        
                            12 Hadziyannis SJ, et al. Peginterferon-2a and Ribavirin
                            Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration
                            and Ribavirin Dose. Ann Intern Med 2004;140(5):346-355.
                        
                        
                            13 Manns MP. et al. Peginterferon alfa-2b Plus Ribavirin
                            Compared With Interferon Alfa-2b Plus Ribavirin for Initial Treatment of Chronic
                            Hepatitis C: A Randomised Trial. The Lancet 2001; 358: 958-965.
                        
                        
                            14 McHutchinson JG, et al. Peginterferon Alfa-2b or
                            Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med
                            2009. 361 (6):580-593.
                        
                        
                            15 Pawlotsky, JM et al. The Hepatitis C Virus Life Cycle
                            as a Target for New Antiviral Therapies. Gastroenterology
                            2007;132:1979-1998.